Theralase Technologies Inc. (TSXV:TLT)

Market Cap	57.44M +11.7%
Revenue (ttm)	802.46K -24.9%
Net Income	-3.79M
EPS	-0.01
Shares Out	310.48M
PE Ratio	n/a
Forward PE	35.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,438
Open	0.1800
Previous Close	0.1750
Day's Range	0.1800 - 0.1850
52-Week Range	0.1450 - 0.4100
Beta	0.41
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TLT

Financial Performance

In 2025, Theralase Technologies's revenue was 816,468, a decrease of -20.99% compared to the previous year's 1.03 million. Losses were -4.12 million, -3.18% less than in 2024.

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Oct 13, 2026

Data Sources Report a data error